MiMedx Q3 swings to $8.68 million net loss year-over-year; Q3 net sales fall 45% to $62.28 million year-over-year
Bitget2026/10/28 20:03- MiMedx swung to a third-quarter 2026 net loss of $8.68 million from year-earlier net income of $16.75 million.
- Net sales fell 45% year-over-year to $62.28 million, with Wound performance hurt by Medicare reimbursement changes.
- Surgical net sales rose 9% year-over-year to $39.96 million, while Wound net sales dropped 71% to $22.32 million.
- A patent license agreement with a wound care competitor will bring in $25 million through five equal installments.
- The 2026 net sales outlook now stands at $250 million to $260 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
